Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery. It works by reducing activity in the vagus nerve, which otherwise signals the vomiting center in the brain; it does not act on dopamine or muscarinic receptors, so it does not help with motion sickness related nausea. It was approved for medical use in the United Kingdom in 1991 and in the United States in 1994. It is available as an oral tablet, an intravenous formulation and a transdermal patch, sold under brand names including Kytril and, for the patch approved in 2008, Sancuso.
Facts
Classification
Approval Status ATC ClassSourced to the subject's own accountA: Alimentary Tract and Metabolism 2 Route of Administration Route of Administration Route of Administration First Approved / Isolated Year Connections
Sources
1. Granisetron (Wikipedia)
2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code AQuote, First-level anatomical group codes, Code A
Alimentary tract and metabolism
3. Granisetron (Wikipedia)
WikipediaInfobox drug, routes_of_administrationQuote, Infobox drug, routes_of_administration
By mouth, intravenous, transdermal
4. Federal Register: Determination That KYTRIL (Granisetron) Was Not Withdrawn for Safety Reasons
Approval historyQuote, Approval history
Kytril (granisetron hydrochloride) Injection was first approved by the FDA in December 1993
Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study (Journal of Neurogastroenterology and Motility, PMC)
Results sectionQuote, Results section
Thirty-nine of the 51 (76%) patients stated improvement with GTS.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.